Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02285852 1999-10-26
PHARMACEUTICAL TABLET COMPRISING
LISINOPRIL DISODIUM AND MICROCRYSTALLINE CELLULOSE
BACKGROUND
Lisinopril is a medicine useful as an ACE inhibitor for treatment of
hypertension. It is sold in Canada and elsewhere in tablets for oral
administration under the tradenames Prinivil~ and Zestril~.
Lisinopril and its use as an ACE inhibitor are disclosed in Canadian patent
number 1275350. Claim 1 of the said patent claims a very wide class of
compounds. Claim 2 specifically claims lisinopril. Claim 3 specifically claims
acid addition salts of lisinopril, and claim 4 specifically claims the
hydrochloride salt.
The lisinopril molecule has two carboxylic acids, so that lisinopril is
capable of
forming alkaline salts, and, in particular, a monosodium salt and a disodium
salt. Moreover, based on the knowledge that enalapril, which a similar
compound, has good stability and high water solubility as the sodium salt,
lisinopril disodium would be expected to be useful as a medicinal ingredient.
Nevertheless Canadian patent number 1275350 makes no explicit disclosure
of lisinopril disodium.
The reason for the lack of any such disclosure appears to be that lisinopril
disodium is extremely hygroscopic and thus very difficult to produce and
isolate in pure form. More particularly, while lisinopril disodium may be
formed by reactian with alkaline sodium compounds in water, it is very
difficult
to remove all of the water to obtain lisinopril disodium in dry form.
Moreover,
even if lisinopril disodium could be obtained in pure dry form, its very
hygroscopic nature would make it difficult to handle and process it into
pharmaceutical compositions.
CA 02285852 1999-10-26
2
In light of the foregoing, the object of the present invention is to enable
the
production of pharmaceutical compositions in the form of tablets for oral
administration comprising lisinopril disodium as the active ingredient.
BRIEF SUMMARY OF THE INVENTION
An aqueous solution of lisinopril disodium is made by dissolving lisinopril
and
sodium hydroxide in water, wherein the amount of sodium hydroxide is
approximately two moles per mole of lisinopril.
The resulting solution is then added to microcrystalline cellulose and mixed
to
form a wet mass, the wet mass is dried to form a dry mass, a lubricant is
added to the dry mass, optionally along with other excipients, such as, for
example, lactose as a filler and croscarmellose sodium as a disintegrant, and
the resulting mixture is processed into tablets on a tablet press.
DETAILED DESCRIPTION OF THE INVENTION
Lisinopril is commercially available as the dehydrate. The molecular weight of
lisinopril anhydrous is 405.5 and that of lisinopril dehydrate is 441.5, so
that
lisinopril dehydrate comprises about 8.2% water.
The molecular weight of sodium hydroxide is 40Ø It follows that dissolving
441.5g (one mole) of lisinopril dehydrate along with 80.Og (two moles) of
sodium hydroxide in water will give a solution of 449.5g lisinopril disodium
(one mole) in water. Lisinopril disodium is freely soluble in water, and the
amount of water needed to dissolve 441.5g of lisinopril dehydrate along with
80.Og of sodium hydroxide is only about 250.Og.
CA 02285852 1999-10-26
3
Because the water needs to be evaporated in a subsequent step, it is
desirable to use as little water as possible to make the solution of
lisinopril
disodium.
As aforesaid, because lisinopril disodium is very hydroscopic, it is difficult
if
not impossible to fully evaporate the water from lisinopril disodium aqueous
solution to form a pure dry material. Accordingly, in order to obtain a dry
powder mixture comprising lisinopril disodium for further processing into
tablets, it is necessary to mix the aqueous solution with a solid excipient
(or a
mixture of solid excipients) to form a wet mass, and then to dry the wet mass.
The quantity of the solid excipient needs to be relatively small, so as to
avoid
the need for the final tablet comprising any given amount of lisinopril
disodium
to be excessively large.
It has been found that water-soluble excipients such as lactose, for example,
are not workable as the excipient. When lactose is used, the affinity of the
lactose for water along with that of the lisinopril disodium makes it
difficult if
not impossible to adequately dry the mass.
It has surprisingly been found that the use of microcrystalline cellulose as
the
excipient to which the solution is added enables drying to form a dry mass
without use of an excessive amount of the excipient and without requiring use
of high temperatures to evaporate the water.
Accordingly, compositions within the scope of the present invention are made
by adding the lisinopril disodium solution to microcrystalline cellulose, and
mixing to form a wet mass.
The amount of microcrystalline cellulose by weight will preferably be from
about 1 part to about 4 parts per part lisinopril disodium, and most
preferably
about 2 to about 3 parts per part lisinopril disodium.
CA 02285852 1999-10-26
4
The wet mass so formed will then be dried to remove most of the water to
give a dry mass in the form of powder or granules suitable for further
processing into tablets. The drying may be done in a conventional oven or a
fluid bed drier, and will preferably be done at a temperature of from about
40°C to about 80°C.
The resultant dried mass will be further processed by adding to it a lubricant
(such as, for example, magnesium stearate) and optionally other excipients,
mixing, and compressing the final mixture into tablets on a tablet press.
The invention will be further understood from the following examples, which
are intended to be illustrative and not limiting of the invention.
E~MPLE 1
2.72 kilos of lisinopril dehydrate was dissolved in 2.0 kilos of water along
with
500.Og of sodium hydroxide. The solution was added to 6.78 kilos of
microcrystalline cellulose, and the resultant mass was mixed to form a
homogeneous wet mass. The wet mass was then dried in a fluid bed drier for
three hours at a temperature of 60°C. The resultant dry powder
consisted of
a mixture of lisinopril disadium and microcrystalline cellulose with a potency
of
about 25%, expressed as lisinopril.
EXAMPLE 2
160.Og of the resultant dry powder from step 1 was mixed with 17.6g of
lactose, 0.8g of croscarmellose sodium, and 1.6g of magnesium stearate.
The mixed powder was then compressed into tablets on a tablet press with a
net weight per tablet of 180 mg.
Each tablet thus contained lisinopril disodium equivalent to about 40 mg of
lisinopril.
